Neurocrine Stock Weak Despite Strong Q2 Beat and Raise; Analysts Call Dip “Overdone”

Neurocrine reported $959M Q2 revenue (+39%) and raised Ingrezza guidance. Stock fell on short-term concerns, but analysts call the dip overdone and raise targets.